Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Fagerstrom Test for Nicotine Dependence (FTND) is a brief smoking dependence scale used to stratify nicotine dependence severity and support cessation planning.
Formula: FTND total = sum of 6 item scores (range 0-10).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The patient answers 6 questions about their current cigarette smoking patterns: time to first cigarette after waking, difficulty refraining in forbidden places, which cigarette they would most hate to give up, cigarettes per day, whether they smoke more in the morning, and whether they smoke even when ill in bed.
Items are scored with different weighting: time to first cigarette (0-3), cigarettes per day (0-3), and other items (0-1 each). Total FTND score ranges from 0 to 10.
0-2 = very low dependence; 3-4 = low; 5 = moderate; 6-7 = high; 8-10 = very high. Higher scores indicate greater physiological nicotine dependence and support more intensive pharmacotherapy (combination NRT or prescription medications) plus behavioral counseling.
Primary Care Physicians
FTND quantifies nicotine dependence severity to guide pharmacotherapy intensity selection during smoking cessation counseling in primary care, where USPSTF recommends tobacco cessation interventions for all tobacco users (Grade A).
Health Coaches & Counselors
Sharing FTND results with patients reinforces that smoking difficulty reflects physiological dependence — not personal weakness — which can normalize the struggle and increase motivation to pursue evidence-based pharmacotherapy.
Pharmacists & Prescribers
FTND score directly guides medication selection: low scores (0-4) may respond to single NRT; moderate scores (5) warrant standard pharmacotherapy; high scores (6-10) benefit from combination NRT (patch + short-acting) or prescription therapy (varenicline, bupropion).
Cessation Program Coordinators
Tobacco cessation programs use FTND at intake to stratify participants by dependence severity, tailor intervention intensity, and predict which participants need more intensive pharmacological and behavioral support to achieve abstinence.
Clinical Researchers
FTND is widely used in smoking cessation clinical trials as a stratification variable at randomization to ensure balanced dependence severity across treatment arms, and as a predictor of treatment response outcomes.
The time to first cigarette after waking is the most powerful predictor of nicotine dependence severity and cessation difficulty. Smoking within 5 minutes indicates severe physiological dependence. This item alone often guides pharmacotherapy intensity more than the total score.
Varenicline (Chantix/Champix) is the most effective single pharmacotherapy for smoking cessation, approximately doubling quit rates compared to placebo (NNT ~8, Cahill et al., Cochrane 2016). It is first-line for patients with FTND ≥5 who are motivated to quit.
Combining a nicotine patch (steady-state delivery) with a short-acting form (gum, lozenge, inhaler) for breakthrough cravings is more effective than patch alone. Combination NRT is recommended for patients with FTND ≥5 who prefer or require non-prescription options.
Bupropion (Wellbutrin/Zyban) improves smoking cessation quit rates and is particularly useful for patients with comorbid depression or a history of depression, where antidepressant effects complement cessation support. It is contraindicated with seizure history or eating disorders.
All pharmacotherapy is significantly more effective when combined with behavioral counseling. Quitlines (1-800-QUIT-NOW in the US) provide free telephone counseling and have been shown to triple success rates. The 5As framework (Ask, Advise, Assess, Assist, Arrange) structures clinical cessation conversations.
Nicotine withdrawal is most intense in the first 24-72 hours after cessation and gradually improves over 2-4 weeks. Patients should be warned about withdrawal symptoms (irritability, anxiety, difficulty concentrating, increased appetite, insomnia) to prevent early relapse during the most difficult period.
E-cigarettes and vaping have controversial evidence for cessation. Some guidelines (NICE, UK) recommend them as harm reduction tools for smokers who have failed NRT and varenicline. US guidelines are more cautious. The evidence base is evolving; FTND-guided discussion can help individualize recommendations.
On average, smokers require 8-11 quit attempts before achieving long-term abstinence. Each attempt provides learning about triggers and barriers. Clinicians should maintain a supportive, non-judgmental approach and not interpret relapse as failure but as a normal part of the cessation process.
The FTND was developed and validated specifically for cigarette smokers. It is not directly applicable to cigar, pipe, smokeless tobacco, or e-cigarette users. Modified versions exist for some non-cigarette products, but standardization is limited.
Fagerström Test for Nicotine Dependence published by Heatherton et al. (Br J Addict 1991) as a revision of the earlier Fagerström Tolerance Questionnaire (1978). Validated across multiple populations with internal consistency α=0.61. Time-to-first-cigarette as the most predictive item: Baker et al. (Nicotine Tob Res 2007). Varenicline efficacy NNT ~8: Cahill et al. (Cochrane 2016). Combination NRT: Fiore et al. 2008 Clinical Practice Guideline (USDHHS). USPSTF Grade A recommendation for tobacco cessation counseling and pharmacotherapy.
Higher FTND scores indicate greater nicotine dependence burden and typically support stronger cessation intervention intensity.
Use during tobacco-use assessment to stratify dependence before counseling and cessation treatment selection.
FTND emphasizes cigarette-smoking behavior and may not fully capture dependence in mixed-product users or non-cigarette nicotine delivery patterns.
For related assessments, see Pack-Year Calculator, COPD GOLD and BODE Index.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate pack-years from cigarettes per day and years smoked. Useful for documenting smoking burden and lung cancer screening discussions.
OpenPulmonologyClassify COPD severity using 2024 GOLD spirometric stages (GOLD 1–4) and ABE exacerbation grouping. Guides inhaler step-up therapy, pulmonary rehabilitation, and oxygen therapy decisions.
OpenPulmonologyEstimate COPD mortality risk with the BODE index using BMI, airflow obstruction, dyspnea grade, and 6-minute walk distance.
Open